Status:
UNKNOWN
The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection
Lead Sponsor:
National Research Institute of Chinese Medicine, Ministry of Health and Welfare
Conditions:
SARS-CoV-2
Covid 19
Eligibility:
All Genders
Brief Summary
Traditional Chinese medicine is regarded as a dietary supplement in many countries around the world. Dietary supplement, NRICM101, has been available for people who diagnosed, suspected or prevented f...
Detailed Description
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is raging around the world. Because of its strong spread, variability, survivability, and invisibility, the number of infected people r...
Eligibility Criteria
Inclusion
- Subjects who confirmed, suspected or prevented infected of COVID 19 disease and take dietary supplement NRICM101
Exclusion
- Those who refuse to participate in observational research.
Key Trial Info
Start Date :
December 23 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
51000 Patients enrolled
Trial Details
Trial ID
NCT04664049
Start Date
December 23 2020
End Date
December 31 2022
Last Update
January 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Research Institute of Chinese Medicine, Ministry of Health and Welfare
Taipei, Taiwan, 11221